A clinical trial of ruxolitinib, an oral JAK-2 inhibitor, is currently ongoing with the aim of investigating its efficacy in the treatment of MDS patients who carry the JAK2 V617F mutation (NCT01895842). Here, JAK2 is linked to myelodysplastic syndrome.